Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer.
Indian journal of cancer（2021）
摘要
The use of neoadjuvant or adjuvant 12-week trastuzumab-paclitaxel in sequence with four anthracycline-based regimens resulted in acceptable long-term outcomes in a group of patients, most of whom had advanced-stage nonmetastatic breast cancer.
更多查看译文
关键词
Adjuvant,neoadjuvant,resource constrained,short course,trastuzumab breast.
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要